Danaher Corporation (DHR) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This summary covers Danaher Corporation's Form 10-Q for the quarterly period ended June 27, 2025. Danaher is a diversified science and technology company operating through three segments: Biotechnology, Life Sciences, and Diagnostics. The company reported a large accelerated filer status with 716 million shares of common stock outstanding as of July 17, 2025.
Key Financial Metrics
| Metric ($ in millions) | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Sales | $5,936 | $5,743 | $11,677 | $11,539 |
| Gross Profit | $3,523 | $3,428 | $7,034 | $6,915 |
| Operating Profit | $760 | $1,168 | $2,034 | $2,480 |
| Net Earnings | $555 | $907 | $1,509 | $1,995 |
| Diluted EPS | $0.77 | $1.22 | $2.10 | $2.68 |
| Operating Cash Flow (YTD) | $2,637 (vs. $3,156 YTD 2024) | |||
| Cash & Equivalents (End of Period) | $2,957 | |||
| Total Debt (Long-term + Current) | $17,355 |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 3.5% in Q2 2025 and 1.0% YTD compared to the prior year. Core sales (excluding currency and acquisitions) grew 1.5% in Q2 and 1.0% YTD.
- Profitability Decline: Operating profit margins decreased significantly, dropping 750 basis points in Q2 (from 20.3% to 12.8%) and 410 basis points YTD (from 21.5% to 17.4%).
- Impairment Charges: The primary driver of the earnings decline was a $432 million noncash impairment charge in Q2 related to a trade name in the Life Sciences segment (genomics consumables). An additional $15 million impairment was recorded in the Biotechnology segment for a facility.
- Segment Performance:
- Biotechnology: Sales up 8.0% QoQ; Operating profit up to $531M.
- Life Sciences: Sales flat (0.5%); Operating loss of $239M due to the impairment charge and lower core sales.
- Diagnostics: Sales up 2.0% QoQ; Operating profit stable at $554M.
- Currency Impact: Foreign currency exchange rates increased reported sales by 2.0% in Q2 2025.
Guidance, Outlook, and Risks
- Tariff Risks: The company anticipates incurring incremental tariff costs of "several hundred million dollars" for the full year 2025 due to new U.S. tariffs and retaliatory measures. Management expects to largely offset these costs through supply chain adjustments and surcharges, but acknowledges potential adverse impacts on revenue and profitability if offsets are insufficient.
- Market Conditions: Demand in academic and government sectors remains weaker due to uncertainty around research funding. High-growth markets were flat year-over-year, with declines in China offset by growth in other regions.
- Tax Outlook: The effective tax rate for the remainder of 2025 is projected to be approximately 17.0%. The company is evaluating the impact of the recently enacted "One Big Beautiful Bill Act" (OBBBA) but does not anticipate a material impact.
- Capital Allocation: The company repurchased approximately $1.1 billion of common stock in the first six months of 2025. Approximately 12 million shares remain available under the current repurchase program. A quarterly dividend of $0.32 per share was declared.
Investor Verification Checklist
- Impairment Details: Verify the specific assumptions used in the $432 million Life Sciences trade name impairment and the remaining useful life (8 years) of the asset.
- Tariff Exposure: Assess the specific magnitude of the "several hundred million dollars" in anticipated tariff costs and the feasibility of passing these costs to customers via surcharges.
- Life Sciences Recovery: Monitor the "genomics consumables" business for signs of demand recovery, particularly regarding the two large customers cited as drivers of the decline.
- Cash Flow Sustainability: Review the $519 million year-over-year decline in operating cash flow to ensure it is not a structural trend driven by working capital inefficiencies.
- Debt Maturity Profile: Confirm the company's ability to refinance the $2.6 billion of borrowings classified as long-term but maturing within one year, relying on the $5.0 billion credit facility.